Physician Education: Bridging Clinical Research and Patient Care

TAM Posttest

Continuing Medical Education Posttest

The following Topics in Antiviral Medicine™ issue offers continuing medical education (CME) credit:

February/March 2017, Volume 25, Issue 1

Overview

  • CME Credit Available: 3.25 AMA PRA Category 1 Credits
  • Release Date: March 30, 2017
  • Expiration Date: March 30, 2018

To complete the activity, read each article and successfully complete the posttest and evaluation form, which will help us evaluate this activity and plan future activities. Your responses will not affect your CME credit.

Learning Objectives

On completion of this activity, participants will be able to:

  • Identify patients with hepatitis C virus (HCV) and advanced fibrosis or cirrhosis
  • Describe the impact of antiretroviral therapy on the risk of kidney disease
  • List the end-organ diseases that are associated with chronic HCV infection
  • Use the updated antiretroviral guidelines from the IAS–USA, including options for initiating antiretroviral therapy in HIV-infected persons, as part of clinical decision-making

Assessment of Needs

The IAS-USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians in the evolving challenges of managing HIV and HCV infection.

Intended Audience

This enduring material is designed for physicians and other health care practitioners who are actively involved in the medical care of people with HIV and HCV infection.

This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.

CME Information

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The IAS–USA designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CME activity is offered from March 30, 2017, to March 30, 2018. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Other health care practitioners will receive a certificate of participation.

Disclosure of Financial Interests

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, authors, IAS–USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing medical education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

Dr Naggie has received research support paid to her institution from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Tacere, and Merck. (Updated 02/28/17)

Dr Verna has received grants awarded to her institution from Salix Pharmaceuticals, Inc. (Updated 03/10/17)

Dr Volberding has served on data and safety monitoring boards for Merck. (Updated 02/13/17)

Dr Wyatt has no relevant financial affiliations to disclose. (Updated 02/28/17)

Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 03/30/17)

The nonstaff members of the Topics in Antiviral Medicine™ Editorial Board participate in a volunteer capacity. They are not compensated for their role in overseeing the program.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors:

Independent educational grants for the 2017 Improving the Management of HIV Disease® CME program:

PLATINUM SUPPORTER
ViiV Healthcare

GOLD SUPPORTER
Gilead Sciences, Inc

SILVER SUPPORTERS
Bristol-Myers Squibb
Janssen Therapeutics

BRONZE SUPPORTER
Merck

Independent educational grants for the 2017 Management of Hepatitis C Virus in the New Era: Small Molecules Bring Big Changes CME program:

GOLD SUPPORTERS
Gilead Sciences, Inc
Merck

BRONZE SUPPORTER
AbbVie

Drug and Product Disclaimer

This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.

The views and opinions expressed herein are those of faculty and do not necessarily represent the opinions or recommendations of IAS–USA.

Contact Information

If you have any questions about this activity, please contact the IAS–USA:

E-mail: journal“at”iasusa.org
Mail: 425 California Street, Suite 1450, San Francisco, CA 94104-2120
Phone: 415-544-9400
Fax: 415-544-9401

By clicking “Begin,” I acknowledge that I have read these instructions and understand them.

You must log in to take the activity.

Begin